Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 13, 2026

Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results

View original at globenewswire.com
Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results WEST PALM BEACH, Fla., July 13, 2026 (GLOBE NEWSWIRE) -- Solitron Devices, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is no assurance that the strategic alternatives review will result in a merger, sale, acquisition, tender offer, or special dividend, and the Company will not make further announcements until the Board approves a specific course of action.

    60% confidence
  • Defense procurement processes tend to move slowly.

    60% confidence
  • The next AMRAAM order is currently expected in the fiscal third quarter.

    60% confidence
  • Net income in the fiscal 2027 first quarter was impacted by a $0.33 million increase to the contingent consideration related to the MEI earn-out payment, based on a large order received after the end of the fiscal quarter.

    60% confidence
  • Revenue is expected to continue at the fiscal Q1 2027 level or greater for the remainder of fiscal year 2027, driven by strong backlog.

    60% confidence
  • No actual income taxes were due despite the income statement reflecting income tax expense, because the Company has deferred tax assets from previous net operating losses.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com